# Evaluation of the Efficacy and Safety of Gelsectan in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome

> **NCT07000383** · NA · RECRUITING · sponsor: **University Medical Center Ho Chi Minh City (UMC)** · enrollment: 90 (estimated)

## Conditions studied

- Diarrhea-predominant Irritable Bowel Syndrome
- Irritable Bowel Syndrome of Diarrhea Type (IBS-D)

## Interventions

- **DEVICE:** Gelsectan
- **DRUG:** Antispasmodic Agent

## Key facts

- **NCT ID:** NCT07000383
- **Lead sponsor:** University Medical Center Ho Chi Minh City (UMC)
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-15
- **Primary completion:** 2026-01-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07000383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07000383, "Evaluation of the Efficacy and Safety of Gelsectan in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT07000383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*